VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTER

佛蒙特州免疫生物学/传染病中心

• 批准号: 8360768
• 负责人: Ralph C Budd
• 金额: $ 89.31万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-20 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360768
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Area; Award; Bioinformatics; Categories; Centers of Research Excellence; Chronic; Communicable Diseases; Educational workshop; Extramural Activities; Faculty; Funding; Genome; Grant; Health; Immune response; Immunology; Infection; Infectious Disease Immunology; Inflammation; Joints; Laboratories; Malignant Neoplasms; Medicine; Mentors; National Center for Research Resources; Pathogenesis; Phase; Pilot Projects; Positioning Attribute; Principal Investigator; Proteomics; Publications; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resources; Scientist; Series; Source; Technology; Thinking; United States National Institutes of Health; Universities; Vermont; Writing; biosafety level 3 facility; career development; college; cost; microbial; multidisciplinary; novel vaccines; planetary Atmosphere; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Regarding AIDS DESCRIPTION (provided by applicant): This application proposes the Phase II COBRE continuation of the Vermont Center for Immunology and Infectious Diseases (VCIID) at the University of Vermont (UVM). During the Phase I COBRE period we created a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The keystone of Phase I was to achieve scientific excellence while building a critical mass of investigators in a vibrant and rigorous atmosphere. A significant component of this was the mentoring of 5 original junior faculty, all of whom obtained extramural funding, had numerous publications and awards, and 4 of 5 have been promoted. We also recruited 5 additional junior faculty in the final two years of Phase I. Already 4 of these 5 new faculty have obtained some extramural funding. In addition, the VCIID-COBRE provided support for cores in Genome Technologies/Bioinformatics, Proteomics, a seminar series of outside experts, a weekly Research-in- Progress forum, retreats, pilot project funding, and workshops on scientific issues, grant writing, and career development. As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence. During Phase II we will continue several of the above successful programs but modify them toward directing the faculty toward becoming a highly interactive group in a mature Center with collaborative grants and sustainability. The new 5 junior faculty will continue their projects for 1-4 additional years. Two senior faculty we be recruited to fill gaps in our intellectual repertoire, one in mucosal immunology to enhance our new Vaccine Trials Center, and the second in chronic infection/inflammation-induced cancer to broaden our thinking to the implications of chronic infectious conditions. Cores will be continued in Genome Technologies/Bioinformatics and Proteomics, with the addition of a new BSL3 facility core to accommodate the growing needs of VCIID investigators desiring to study BSL3 agents. Also in this area, we will form a unique partnership among the VCIID, UVM, and the Vermont Department of Health in which the State will build a new Department of Health laboratory building on the UVM campus attached to our research building containing the BSL3 facility. This will provide space for an expanded joint BSL3 facility to include animal and select agent use. These endeavors will position us to be competitive for new POI and U19 category grants.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 关于艾滋病 描述（由申请人提供）：本申请提出了佛蒙特大学免疫学和传染病中心（VCIID）（UVM）（UVM）的II期柯布雷延续。在第I阶段的毛茸茸时期，我们创建了一个多学科的科学家和临床医生，从事微生物发病机理和对感染的免疫反应进行合作研究。第一阶段的基石是在充满活力和严格的氛围中建立大量研究人员的同时，取得卓越的卓越。其中一个重要的组成部分是对5名原始初级教师的指导，所有这些教师都获得了校外资金，获得了许多出版物和奖项，而5名中有4个被提升。我们还在第一阶段的最后两年中招募了另外5名初级教师。这5位新教师中有4个已经获得了一些校外资金。此外，VCIID-Cobre为基因组技术/生物信息学，蛋白质组学，外部专家的研讨会系列，每周一次的研究论坛，务虚会，试点项目资助以及有关科学问题，赠款，赠款写作和职业发展的研讨会提供了支持核心的支持。 As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence.在第二阶段，我们将继续以上几个成功的计划，但将其修改为指导教师成为一个具有协作赠款和可持续性成熟中心的高度互动群体。新的5名初级教师将继续他们的项目1-4年。我们被招募了两位高级教师，以填补我们的智力曲目中的空白，其中一项是粘膜免疫学，以增强我们的新疫苗试验中心，第二个是慢性感染/炎症引起的癌症的第二个，以扩大我们的思维，以使我们的思维范围扩大了慢性感染状况的影响。基因组技术/生物信息学和蛋白质组学将继续进行核心，并增加了新的BSL3设施核心，以适应希望研究BSL3药物的VCIID研究人员的不断增长的需求。同样在这一领域，我们将在VCIID，UVM和佛蒙特州卫生部之间建立独特的合作伙伴关系，在该卫生部将在我们的研究大楼附属于包含BSL3设施的UVM校园上建造新的卫生部实验室大楼。这将为扩展的关节BSL3设施提供空间，以包括动物和精选剂使用。这些努力将使我们对新POI和U19类别的赠款有竞争力。